Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040469 · ClinicalTrials.gov registry record · Phase 2
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
A Phase 2 study, sponsored by Baylor College of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00040469 is a Phase 2 study that was terminated before completion, run by Baylor College of Medicine. The registered enrollment target is 15 participants.
The verdict
NCT00040469, a Phase 2 study, was terminated before completion, sponsored by Baylor College of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- DRUG Dilantin
- DRUG Campath -1H
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2000-08 |
| Est. Completion | 2003-11-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00040469
The ClinicalTrials.gov registry entry for NCT00040469 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT00040469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00040469 about?
NCT00040469 is a clinical study titled "Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies". The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.
What is the current status of trial NCT00040469?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2000-08. Estimated completion is 2003-11-21.
What interventions are being tested in trial NCT00040469?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Dilantin (DRUG), Campath -1H (DRUG).
Who is sponsoring clinical trial NCT00040469?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.